OTCMKTS:CTYX Curative Biotechnology (CTYX) Stock Price, News & Analysis → Are You Positioned For The New Energy Goldrush? (From Wealthpin Pro) (Ad) Free CTYX Stock Alerts $0.02 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.0190▼$0.019550-Day Range$0.01▼$0.0352-Week Range$0.00▼$0.22Volume52,500 shsAverage Volume3.01 million shsMarket Capitalization$7.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Curative Biotechnology alerts: Email Address Ad Wealthpin ProAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Curative BiotechnologyCurative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. Its products include MedFlash, electronic Personal Health Manager, Medical Alert, personal emergency response services, product and medical transcription, disease management, revenue cycle management, and medical consulting-billing. The company was founded by Jon Pevzner on July 29, 1995 and is headquartered in Boca Raton, FL.Read More CTYX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTYX Stock News HeadlinesOctober 31, 2023 | tmcnet.comCurative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of DirectorsMay 17, 2023 | finance.yahoo.comCurative Announces Spin-Off of Sensible Diagnostics with their Game-Changing 10-Minute Point-Of-Care PCR Testing PlatformMay 16, 2023 | finance.yahoo.comSOLVE FSHD Invests in Epic Bio to Advance Potentially Curative TherapyJanuary 5, 2023 | wsj.comCurative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop StudyNovember 29, 2022 | msn.comAstraZeneca acquires biotech Neogene for $320M in bid to expand cancer treatmentsSeptember 12, 2022 | apnews.comArbor Biotechnologies Named One of Fierce Biotech’s “Fierce 15” Companies of 2022June 9, 2022 | apnews.com4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A FinancingSee More Headlines Receive CTYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curative Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolOTCMKTS:CTYX CUSIPN/A CIKN/A Webwww.connectyx.com Phone(561) 418-7725FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares388,504,000Free FloatN/AMarket Cap$7.46 million OptionableNot Optionable Beta-33.99 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesPaul M. MichaelExecutive Chairman & PresidentI. Richard GarrChief Executive Officer & General CounselRon BordensExecutive VP-Technical Operations & ManufacturingBarry A. GinsbergVice Chairman & Chief Strategy OfficerKey CompetitorsPacific Health Care OrganizationOTCMKTS:PFHODBioRestorative TherapiesOTCMKTS:BRTXQHemaCareOTCMKTS:HEMAKnow LabsOTCMKTS:KNWNOnion GlobalNYSE:OGView All Competitors CTYX Stock Analysis - Frequently Asked Questions How have CTYX shares performed in 2024? Curative Biotechnology's stock was trading at $0.0213 at the beginning of 2024. Since then, CTYX shares have decreased by 10.8% and is now trading at $0.0190. View the best growth stocks for 2024 here. How do I buy shares of Curative Biotechnology? Shares of CTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CTYX) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks MediaElon Musk’s Final Masterpiece: “X-9840”Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curative Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.